Why Shares In Clinigen Group PLC Jumped More Than 10% Today

 Clinigen Group PLC (LON: CLIN) jumps on acquisition of Idis Group Holdings Limited.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Clinigen (LSE: CLIN), the speciality pharmaceutical company, surged more than 10% in early trade today after the company announced that it has agreed to acquire Idis Group Holdings Limited. The deal will create a market leader in the market for the supply of ethical unlicensed medicines. 

With over 25 years of history behind it, Idis is a strong brand and a perfect acquisition for Clinigen. The company is a global market leader in providing access to unlicensed medicines in over 100 countries. Idis is already the leading supplier for ethical on-demand products to UK hospitals, and the global market is estimated to be worth more than $5bn per annum. 

Clinigen is paying £225m for Idis. The deal will be financed by a fully underwritten vendor placing to raise £135m. An additional £104m will be drawn down under Clinigen’s new debt facilities. 

In the year to 28 February 2015, Idis reported revenue of £197m and adjusted earnings before interest, tax, depreciation and amortisation of £15.6m. 

 Commenting on the deal Peter George, Chief Executive Officer of Clinigen, said:

“This acquisition satisfies a number of our key strategic goals – achieving the market leader position in the $5+ billion unlicensed medicine supply sector and strengthening our leading position in the $2 billion clinical trial supply market…The acquisition will also accelerate our growth and gives us a much better balanced portfolio of businesses, whilst extending our unique business model.”

Market leader

A merged Clinigen-Idis will create a market leader in the $5bn market for the supply of ethical unlicensed medicines. And the enlarged group’s size should help it grab an even greater share of the market.  

According to Clinigen’s management, the acquisition is expected to be immediately earnings enhancing. £2.5m of annual cost synergies have already been identified. Moreover, Clinigen’s management believes that opportunities for further revenue and cost synergies are likely to be identified.

That being said, looking at Idis’ historic figures the group is hardly a star performer.

Gross profit has fallen by more than 10% over the past three years, despite a 23% increase in sales. Profit before tax has also fallen over the past three years from £11m to £7.8m.

Meanwhile, over the past two years net debt has more than doubled while shareholder equity has slumped from £2.7m, down to negative £14.9m. Idis was also forced to undergo a significant restructuring during 2013.

High valuation 

Idis’ historic figures are not overly impressive but by combining with Clinigen, the two companies will be a force to be reckoned with. 

As of yet, City analysts have not had a chance to weigh in on the deal. Still, based on current figures, Clinigen is currently trading at a forward P/E of 21.4, a high valuation that leaves little room for error if the Idis deal fails to yield results.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended Clinigen. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Fans of Warren Buffett taking his photo
Investing For Beginners

This billionaire is copying Warren Buffett. Should I do the same?

Jon Smith reviews fresh news about how an investment billionaire is imitating Warren Buffett as he goes after an interesting…

Read more »

Investing Articles

I expect these 3 FTSE 100 shares to fly when inflation really starts to fall

Harvey Jones picks out three FTSE 100 shares whose fortunes should improve once inflation is finally on the run. They're…

Read more »

Investing Articles

After a positive Q4 update, is the Vistry share price set to bounce back?

The Vistry share price has been falling sharply as a result of cost issues in its South Division. But the…

Read more »

Investing Articles

Is it game over for the Diageo share price?

The Diageo share price is showing as much spirit as an alcohol-free cocktail. Harvey Jones is wondering whether he should…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 key reasons why AstraZeneca’s share price looks a steal to me right now

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be…

Read more »

Investing Articles

Here’s how investors could aim for a £6,531 annual passive income from £11,000 of Aviva shares

As a stock’s yield rises when its price falls, I'm not bothered by Aviva shares’ apparent inability to break the…

Read more »

Investing Articles

3 million reasons why earning a second income is more important than ever

With AI posing a threat to UK jobs, our writer considers ways to earn a second income by investing in…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

With an 8% yield, is the second-largest FTSE 250 stock worth considering?

Our writer considers the value of the second-largest stock on the FTSE 250 with a £4bn market cap and a…

Read more »